Candriam S.C.A. Purchases Shares of 467,562 Teva Pharmaceutical Industries Ltd. $TEVA

Candriam S.C.A. purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 467,562 shares of the company’s stock, valued at approximately $14,083,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $25,000. Allworth Financial LP grew its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust grew its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of NYSE:TEVA opened at $32.82 on Monday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The company’s fifty day moving average is $34.14 and its 200-day moving average is $32.69. The company has a market capitalization of $37.74 billion, a PE ratio of 24.68, a P/E/G ratio of 4.02 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion during the quarter. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 465,931 shares of company stock valued at $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on TEVA shares. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday. Barclays lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.